Loss of heterozygosity and microsatellite instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer

Shen, Xing Jun; Ali-Fehmi, Rouba; Weng, Chang Ren; Sarkar, Fazlul H.; Grignon, David J.; Liao, D. Joshua

doi:10.4161/cbt.5.5.2610

Cited by 11 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High frequencies of LOH observed at sites on chromosome Xq in human cancers of the breast (50), uterine cervix (51), and lung (52) suggest the presence of important tumor suppressor genes in this region. Moreover, there are reports of frequent LOH at chromosome Xq28, where ARD1 is located (53), in ovarian cancer (54) and cervical carcinoma (55). Here, we showed that LOH of ARD1 occurs in human breast, lung, pancreatic, and ovarian cancer samples, further supporting a role for ARD1 in cancer development.…”

Section: Discussionmentioning

confidence: 99%

ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway

et al. 2010

View full text Add to dashboard Cite

Mammalian target of rapamycin (mTOR) regulates various cellular functions, including tumorigenesis, and is inhibited by the tuberous sclerosis 1 (TSC1)–TSC2 complex. Here, we demonstrate that arrest-defective protein 1 (ARD1) physically interacts with, acetylates, and stabilizes TSC2, thereby repressing mTOR activity. The inhibition of mTOR by ARD1 inhibits cell proliferation and increases autophagy, thereby inhibiting tumorigenicity. Correlation between ARD1 and TSC2 abundance was apparent in multiple tumor types. Moreover, evaluation of loss of heterozygosity at Xq28 revealed allelic loss in 31% of tested breast cancer cell lines and tumor samples. Together, our findings suggest that ARD1 functions as an inhibitor of the mTOR pathway and that dysregulation of the ARD1-TSC2-mTOR axis may contribute to cancer development.

show abstract

Section: Discussionmentioning

confidence: 99%

ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The expression level is higher in mature ovary than in immature ovary of Penaeus monodon 16 . High frequencies of loss of heterozygosity and microsatellite instability at the Xq28 and of the A/G heterozygosity at the 605th nucleotides of the RPL10 gene may be associated with OC 32 . Our study showed that RPL10 was overexpressed in OC cell line and OC tissues, including serous, mucinous, endometrioid, transitional cell, and clear cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer

et al. 2018

View full text Add to dashboard Cite

Ribosomal protein L10 (RPL10) is one of large ribosomal proteins and plays a role in Wilms' tumor and premature ovarian failure. However, the function of RPL10 in human epithelial ovarian cancer (EOC) remains unknown. The purpose of this study was to examine the expression level and function of RPL10 in EOC. RPL10 protein expression was detected by immunohistochemistry and Western blot. The association RPL10 expression with clinical features was analyzed. Loss-of-function and gain-of-function approaches were applied in cellular assays, including cell viability, migration, invasion, and apoptosis. Our study demonstrated for the first time that RPL10 was upregulated in human EOC compared with normal ovarian tissues. Knockdown of RPL10 inhibited cell viability, migration, and invasion, and increased cell apoptosis. On the contrary, upregulation of RPL10 increased cell viability, migration, invasion, and decreased cell apoptosis. Furthermore, miR-143-3p regulated RPL10 expression. Our data indicate that RPL10 is a potential tissue biomarker of patients with EOC and may be a therapeutic target of ovarian cancer.

show abstract

“…In the context of solid tumors, RPL10's contribution in driving oncogenic processes has been suggested in pancreatic [50,54], prostatic [81], ovarian [12,82], and theratoid/rhabdoid tumors [83].…”

Section: Rpl10: a Player In Cancermentioning

confidence: 99%

Ribosomal Protein L10: From Function to Dysfunction

Pollutri

Penzo

2020

Cells

View full text Add to dashboard Cite

Eukaryotic cytoplasmic ribosomes are highly structured macromolecular complexes made up of four different ribosomal RNAs (rRNAs) and 80 ribosomal proteins (RPs), which play a central role in the decoding of genetic code for the synthesis of new proteins. Over the past 25 years, studies on yeast and human models have made it possible to identify RPL10 (ribosomal protein L10 gene), which is a constituent of the large subunit of the ribosome, as an important player in the final stages of ribosome biogenesis and in ribosome function. Here, we reviewed the literature to give an overview of the role of RPL10 in physiologic and pathologic processes, including inherited disease and cancer.

show abstract

Loss of heterozygosity and microsatellite instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer

Cited by 11 publications

References 24 publications

ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway

ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway

Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer

Ribosomal Protein L10: From Function to Dysfunction

Contact Info

Product

Resources

About